Gastrointestinal Stromal Tumors (GIST)

  • most common mesenchymal neoplasms of GI
  • liver and/or dissemination within the abdominal cavity are the most common clinical manifestations of malignancy'

Evaluation and Workup

  • CD117 (reflecting the KIT receptor tyrosine kinase)


  • Primary treatment is surgery, but surgery does not routinely cure GIST
  • Adjuvant gleevac for complete resection for at least 12 months in patients with intermediate to high-risk GIST
  • Imatinib (Gleevac), a selective inhibitor of the KIT has produced durable clinical benefit (50% response rate)
  • documented resistance to conventional chemotherapies
  • RT is considered for palliation
Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-Share Alike 2.5 License.